Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 5, 2007, Pages 1401-1410

  Vavassori, Vittorio ^a   Fiorino, Claudio ^b   Rancati, Tiziana ^c   Magli, Alessandro ^a   Fellin, Gianni ^d   Baccolini, Michela ^e   Bianchi, Carla ^a   Cagna, Emanuela ^f   Mauro, Flora A ^e   Monti, Angelo F ^f,g   Munoz, Fernando ^f,g   Stasi, Michele ^g   Franzone, Paola ^h   Valdagni, Riccardo ^c  

^a OSPEDALE DI CIRCOLO   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e MARIA CECILIA HOSPITAL   (Italy)

^f SANT ANNA HOSPITAL   (Italy)

^g CANDIOLO CANCER INSTITUTE   (Italy)

^h C Arrigo Children's Hospital   (Italy)

Author keywords

Acute toxicity; Conformal radiotherapy; Prostate radiotherapy; Rectal toxicity

Indexed keywords

HORMONES; ONCOLOGY; PARAMETER ESTIMATION; RADIOTHERAPY; TOXICITY; TUMORS;

ACUTE TOXICITY; CONFORMAL RADIOTHERAPY; MULTIVARIATE ANALYSES; PROSTATE RADIOTHERAPY; RECTAL TOXICITY;

PATIENT MONITORING;

ANTIANDROGEN; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BICALUTAMIDE; CYPROTERONE ACETATE; GONADORELIN DERIVATIVE; HORMONE; INSULIN;

ACUTE TOXICITY; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; FECES INCONTINENCE; HEMORRHOID; HUMAN; INTESTINE INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE; RADIATION INJURY; RECTUM HEMORRHAGE; RECTUM INJURY; TENESMUS;

ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; HEMORRHOIDS; HUMANS; INTESTINES; MALE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM; REGRESSION ANALYSIS; RISK FACTORS;

EID: 33947496935     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.10.040     Document Type: Article

References (43)

1. Hanks G.E., Martz K.L., and Diamond J.J. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15 (1988) 1299-1305
2. Zietman A.L., Coen J.J., Dallow K.C., et al. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome. Int J Radiat Oncol Biol Phys 32 (1995) 287-292
3. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
4. Michalski J.M., Winter K., Purdy J.A., et al. Trade-off to low grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Semin Radiat Oncol 12 Suppl. 1 (2002) 75-80
5. Pollack A., Zagars G., Starskschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
6. Perez C.A., Michalski J.M., Purdy J.A., et al. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: Preliminary results of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 47 (2000) 629-637
7. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
8. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
9. Kupelian P.A., Reddy C.A., Carlson T.P., et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 904-912
10. Boersma L.J., van den Brink M., Allison M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41 (1998) 83-92
11. Cozzarini C., Fiorino C., Ceresoli G.L., et al. Significant correlation between rectal DVH and late rectal bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 55 (2003) 688-694
12. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose conformal radiotherapy for localized prostate cancer. J Radiat Oncol Biol Phys 57 (2003) 953-962
13. Fiorino C., Cozzarini C., Vavassori V., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: Analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
14. Huang E.H., Pollack A., Levy L., et al. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1009-1019
15. Karlsdottir A., Johannessen D.C., Muren P.L., et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 71 (2004) 43-53
16. Nuyttens J.J., Milito S., Rust P.F., et al. Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol 64 (2002) 209-214
17. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
18. Zapatero A., Garcia-Vicente F., Modolell I., et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: Dose-volume effect. Int J Radiat Oncol Biol Phys 59 (2004) 1343-1351
19. Peeters S.T., Hoogeman M.S., Heemsbergen W.D., et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
20. Vargas C., Martinez A., Kestin L.L., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 1297-1308
21. Dorr W., and Hendry J.H. Consequential late effects in normal tissues. Radiother Oncol 61 (2001) 223-231
22. Deham J.W., O'Brien P.C., Dunstan R.H., et al. Is there more than one late radiation proctitis syndrome?. Radiother Oncol 51 (1999) 43-53
23. Dale W., Campbell T., Ignacio L., et al. Self-assessed health related quality of life in men being treated for prostate cancer with radiotherapy: Instrument validation and its relation to patient assessed bother or symptoms. Urology 53 (1999) 359 366
24. Rancati T., Fiorino C., Gagliardi G., et al. Fitting late rectal bleeding data using different NTCP models: Results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 73 (2004) 21-32
25. Fiorino C., Gianolini S., and Nahum A.E. A cylindrical model of the rectum: Comparing dose-volume, dose-surface and dose-wall histograms in the radiotherapy of prostate cancer. Phys Med Biol 48 (2003) 2603-2616
26. Foppiano F., Fiorino C., Frezza G., et al. The impact of contouring uncertainty on rectal 3D dose-volume data: Results of a dummy run in a multicenter trial (AIROPROS01-02). Int J Radiat Oncol Biol Phys 57 (2003) 573-579
27. Declich F., Fiorino C., Masi L., et al. Comparing rectal DVH calculation with four commercial treatment planning systems by means of the AAPM TG23 18 MV. [Abstract]. Radiother Oncol 64 Suppl. 1 (2002) S318
28. Muanza T.M., Albert P.S., Smith S., et al. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 1316-1321
29. Talcott J.A., Manola J., Clark J.A., et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 21 (2003) 3979-3986
30. Goldner G., Wachter-Gerstner N., Wachter S., et al. Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer: Differences between patient's self-reported questionnaire and the corresponding doctor's report. Strahlenther Onkol 179 (2003) 320-327
31. Zelefsky M.J., and Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 49 3A Suppl (1997) 38-45
32. Tsai H.K., Manola J., Abner A., et al. Patient-reported acute GI toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy. Urol Oncol 23 (2005) 230-237
33. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1142-1152
34. Valicenti R.K., Winter K., Cox J.D., et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?. Int J Radiat Oncol Biol Phys 57 (2003) 614-620
35. Zapatero A., Alcantara P., Valcarcel F., et al. Preliminary report of a multicenter Spanish trial (GICOR 05) of risk-adapted androgen ablation combined with dose-escalation 3D conformal therapy for prostate cancer: Impact on early toxicity. [Abstract]. Int J Radiat Oncol Biol Phys 57 Suppl 1 (2003) S391-S392
36. Lilleby W., Dale E., Olsen D.R., et al. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose. Acta Oncol 42 (2003) 10-14
37. Sanguineti G., Marcenaro M., Franzone P., et al. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. Radiother Oncol 66 (2003) 151-157
38. Lilleby W., Fossa S.D., Knutsen B.H., et al. Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother Oncol 57 (2000) 195-200
39. Herold D.M., Hanlon A.L., and Hanks G.E. Diabetes mellitus: A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 475-479
40. Denham J.W., and Hauer-Jensen M. The radiotherapeutic injury-A complex "wound.". Radiother Oncol 63 (2002) 129-145
41. Chon B.H., and Loeffler J.S. The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist 7 (2002) 136-143
42. Liu M., Pickles T., Agranovich A., et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 59-67
43. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713